Neuroendocrine Tumor Treatment Global Market Report 2024

Description

Neuroendocrine tumor treatment encompasses a spectrum of medical interventions and therapies designed to effectively manage and control neuroendocrine tumors (NETs). These rare cancers originate from neuroendocrine cells responsible for regulating hormone production throughout the body. The overarching goal of neuroendocrine tumor treatment is to address tumor growth, alleviate symptoms, and enhance the overall quality of life for patients.

The primary categories of products utilized in neuroendocrine tumor treatment include somatostatin analogs (SSAs), targeted therapy, chemotherapy, and other complementary approaches. Somatostatin analogs (SSAs) are synthetic drugs engineered to replicate the actions of somatostatin, a naturally occurring hormone in the body. These analogs find application in various indications, including those affecting the lungs, pancreas, gastrointestinal system, and other relevant areas. Neuroendocrine tumor treatment products are commonly employed by medical facilities such as hospitals, oncology centers, and other healthcare institutions dedicated to providing comprehensive care for patients grappling with neuroendocrine tumors.

The neuroendocrine tumor treatment market research report is one of a series of new reports from The Business Research Company that provides neuroendocrine tumor treatment market statistics, including neuroendocrine tumor treatment industry global market size, regional shares, competitors with a neuroendocrine tumor treatment market share, detailed neuroendocrine tumor treatment market segments, market trends and opportunities, and any further data you may need to thrive in the neuroendocrine tumor treatment industry. This neuroendocrine tumor treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neuroendocrine tumor treatment market size has grown rapidly in recent years. It will grow from $1.94 billion in 2023 to $2.16 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The expansion observed in the historical period can be ascribed to factors such as progress in clinical research and understanding, increased awareness and education, the availability of specialized medical expertise, advancements in radiation therapy, and the provision of supportive care services.

The neuroendocrine tumor treatment market size is expected to see rapid growth in the next few years. It will grow to $3.19 billion in 2028 at a compound annual growth rate (CAGR) of 10.3%. The anticipated growth in the upcoming period can be attributed to advancements in precision medicine, innovations in immunotherapy, the increasing adoption of minimally invasive procedures, a rise in incidence rates, and the expanding utilization of telemedicine and remote care. Key trends expected in the forecast period encompass advancements in diagnostic technologies, progress in peptide receptor radionuclide therapy (PRRT), the integration of nanotechnology in drug delivery, the emergence of novel radiopharmaceuticals, and the fostering of cross-disciplinary collaboration.

The anticipated growth in the neuroendocrine tumor treatment market is expected to be propelled by the increasing prevalence of neuroendocrine tumors (NETs). These rare tumors, originating from neuroendocrine cells, necessitate essential treatment to address symptoms, control tumor growth, and utilize radiation therapy for targeted cell destruction. Notably, in March 2023, the American Society of Clinical Oncology (ASCO) reported that over 12,000 people in the United States are diagnosed with neuroendocrine tumors annually, and approximately 171,000 individuals are living with this diagnosis in 2023. Similarly, Cancer Australia, in August 2022, revealed that 5,437 people were diagnosed with neuroendocrine tumors in Australia in 2022, constituting 3.4% of all new cases for that year. The growing prevalence of neuroendocrine tumors is thus a significant driver fueling the expansion of the neuroendocrine tumor treatment market.

The growth of the neuroendocrine tumor treatment market is expected to be boosted by increasing government funding for research and development. Government funding plays a pivotal role in advancing tumor research and treatment by providing financial support for scientific studies, medical infrastructure, and enhanced access to care. This support contributes to improvements in cancer prevention, diagnosis, and overall patient outcomes. As an illustration, in September 2023, the National Cancer Institute, a US-based government agency, received a budget of $7.3 billion from the United States Congress for fiscal year 2023, representing a $408 million increase compared to the previous year. The substantial increase in government funding for research and development underscores its crucial role in driving advancements in neuroendocrine tumor treatment and contributing to the growth of the market.

Clinical drug development for neuroendocrine tumor treatment stands out as a prominent trend gaining traction in the market. Major companies within the neuroendocrine tumor treatment sector are actively engaged in developing innovative therapies to maintain their competitive positions. A noteworthy example is Viewpoint Molecular Targeting, Inc., a US-based pharmaceutical company, which, in October 2022, announced the FDA's fast-track designation for [212Pb] VMT-α-NET. This targeted alpha-particle therapy (TAT) is designed for patients with SSTR2-positive unresectable or metastatic neuroendocrine tumors (NETs). The fast-track designation by the FDA is intended to expedite the development and review process for [212Pb] VMT-α-NET, recognizing its potential to significantly improve safety or effectiveness in treating a severe condition.

Companies operating in the neuroendocrine tumor treatment market are strategically focusing on securing research funding to gain a competitive edge. Research funding, provided by various entities including government agencies, private foundations, corporations, and non-profit organizations, plays a crucial role in advancing product development and clinical trials. For instance, Ariceum Therapeutics GmbH, a Germany-based company, successfully raised EUR 25 million in June 2022 as part of its Series A financing. An additional EUR 22.75 million was raised in a Series A extension financing, supporting the further development of their lead product, Satoreotide, intended for treating low- and high-grade neuroendocrine cancers. These funds contribute to advancing Ariceum's clinical pipeline, particularly focusing on their lead radiopharmaceutical product.

In November 2022, Lantheus Holdings Inc., a US-based healthcare company specializing in diagnostic imaging products, entered into a collaboration with Point Biopharma Global Inc., a US-based radiopharmaceutical company, for a significant sum of $260 million. This collaboration aims to leverage Lantheus Holdings Inc.'s commercial expertise and global reach alongside Point Biopharma's innovative radiopharmaceutical technology. The partnership seeks to accelerate the development and commercialization of PNT2002 and PNT2003, contributing to the advancement of transformative therapies for patients with cancer, particularly in the neuroendocrine tumor treatment space.

Major companies operating in the neuroendocrine tumor treatment market report are Pfizer Inc., F Hoffmann-La Roche AG, AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca, GlaxoSmithKline PLC, Takeda Pharmaceutical, Eli Lilly And Company, Amgen Inc., Merck & Co. Inc., Boehringer Ingelheim International GmbH, Servier, Teva Pharmaceutical Industries Ltd., Ipsen Pharma SAS, Exelixis Inc., Advanced Accelerator Applications SA, Hutchison Medipharma Ltd., Dauntless Pharmaceuticals Inc., Tarveda Therapeutics, GlycoMira Therapeutics Inc., AVEO Pharmaceuticals Inc., Progenics Pharmaceuticals Inc., Callisto Pharmaceuticals Pvt Ltd., Chiasma Inc.

North America was the largest region in the neuroendocrine tumor treatment market in 2023. The regions covered in the neuroendocrine tumor treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neuroendocrine tumor treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neuroendocrine tumor treatment market includes of revenues earned by entities by providing neuroendocrine tumor treatment services such as surgery, radiation therapy, peptide receptor radionuclide therapy, somatostatin analogs, diagnosis, staging and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neuroendocrine Tumor Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neuroendocrine tumor treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neuroendocrine tumor treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neuroendocrine tumor treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Product: Somatostatin Analogs (SSAs); Targeted Therapy; Chemotherapy; Others Products
2) By Indication: Lungs; Pancreas; Gastrointestinal; Others Indications
3) By End-Users: Hospitals; Oncology Centers; Other End-Users
Companies Mentioned: Pfizer Inc.; F Hoffmann-La Roche AG; AbbVie Inc.; Novartis AG; Sanofi SA
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r13766

1. Executive Summary

2. Neuroendocrine Tumor Treatment Market Characteristics

3. Neuroendocrine Tumor Treatment Market Trends And Strategies

4. Neuroendocrine Tumor Treatment Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Neuroendocrine Tumor Treatment Market Size and Growth

5.1. Global Neuroendocrine Tumor Treatment Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Neuroendocrine Tumor Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Neuroendocrine Tumor Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Neuroendocrine Tumor Treatment Market Segmentation

6.1. Global Neuroendocrine Tumor Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Somatostatin Analogs (SSAs)
Targeted Therapy
Chemotherapy
Other Products
6.2. Global Neuroendocrine Tumor Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Lungs
Pancreas
Gastrointestinal
Other Indications
6.3. Global Neuroendocrine Tumor Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Oncology Centers
Other End-Users

7. Neuroendocrine Tumor Treatment Market Regional And Country Analysis

7.1. Global Neuroendocrine Tumor Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Neuroendocrine Tumor Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Neuroendocrine Tumor Treatment Market

8.1. Asia-Pacific Neuroendocrine Tumor Treatment Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Neuroendocrine Tumor Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Neuroendocrine Tumor Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Neuroendocrine Tumor Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Neuroendocrine Tumor Treatment Market

9.1. China Neuroendocrine Tumor Treatment Market Overview
9.2. China Neuroendocrine Tumor Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Neuroendocrine Tumor Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Neuroendocrine Tumor Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Neuroendocrine Tumor Treatment Market

10.1. India Neuroendocrine Tumor Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Neuroendocrine Tumor Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Neuroendocrine Tumor Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Neuroendocrine Tumor Treatment Market

11.1. Japan Neuroendocrine Tumor Treatment Market Overview
11.2. Japan Neuroendocrine Tumor Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Neuroendocrine Tumor Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Neuroendocrine Tumor Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Neuroendocrine Tumor Treatment Market

12.1. Australia Neuroendocrine Tumor Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Neuroendocrine Tumor Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Neuroendocrine Tumor Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Neuroendocrine Tumor Treatment Market

13.1. Indonesia Neuroendocrine Tumor Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Neuroendocrine Tumor Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Neuroendocrine Tumor Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Neuroendocrine Tumor Treatment Market

14.1. South Korea Neuroendocrine Tumor Treatment Market Overview
14.2. South Korea Neuroendocrine Tumor Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Neuroendocrine Tumor Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Neuroendocrine Tumor Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Neuroendocrine Tumor Treatment Market

15.1. Western Europe Neuroendocrine Tumor Treatment Market Overview
15.2. Western Europe Neuroendocrine Tumor Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Neuroendocrine Tumor Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Neuroendocrine Tumor Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Neuroendocrine Tumor Treatment Market

16.1. UK Neuroendocrine Tumor Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Neuroendocrine Tumor Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Neuroendocrine Tumor Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Neuroendocrine Tumor Treatment Market

17.1. Germany Neuroendocrine Tumor Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Neuroendocrine Tumor Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Neuroendocrine Tumor Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Neuroendocrine Tumor Treatment Market

18.1. France Neuroendocrine Tumor Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Neuroendocrine Tumor Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Neuroendocrine Tumor Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Neuroendocrine Tumor Treatment Market

19.1. Italy Neuroendocrine Tumor Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Neuroendocrine Tumor Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Neuroendocrine Tumor Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Neuroendocrine Tumor Treatment Market

20.1. Spain Neuroendocrine Tumor Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Neuroendocrine Tumor Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.4. Spain Neuroendocrine Tumor Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Neuroendocrine Tumor Treatment Market

21.1. Eastern Europe Neuroendocrine Tumor Treatment Market Overview
21.2. Eastern Europe Neuroendocrine Tumor Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Neuroendocrine Tumor Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Neuroendocrine Tumor Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Neuroendocrine Tumor Treatment Market

22.1. Russia Neuroendocrine Tumor Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Neuroendocrine Tumor Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Neuroendocrine Tumor Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Neuroendocrine Tumor Treatment Market

23.1. North America Neuroendocrine Tumor Treatment Market Overview
23.2. North America Neuroendocrine Tumor Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Neuroendocrine Tumor Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Neuroendocrine Tumor Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Neuroendocrine Tumor Treatment Market

24.1. USA Neuroendocrine Tumor Treatment Market Overview
24.2. USA Neuroendocrine Tumor Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Neuroendocrine Tumor Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Neuroendocrine Tumor Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Neuroendocrine Tumor Treatment Market

25.1. Canada Neuroendocrine Tumor Treatment Market Overview
25.2. Canada Neuroendocrine Tumor Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Neuroendocrine Tumor Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Neuroendocrine Tumor Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Neuroendocrine Tumor Treatment Market

26.1. South America Neuroendocrine Tumor Treatment Market Overview
26.2. South America Neuroendocrine Tumor Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Neuroendocrine Tumor Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Neuroendocrine Tumor Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Neuroendocrine Tumor Treatment Market

27.1. Brazil Neuroendocrine Tumor Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Neuroendocrine Tumor Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Neuroendocrine Tumor Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Neuroendocrine Tumor Treatment Market

28.1. Middle East Neuroendocrine Tumor Treatment Market Overview
28.2. Middle East Neuroendocrine Tumor Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Neuroendocrine Tumor Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Neuroendocrine Tumor Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Neuroendocrine Tumor Treatment Market

29.1. Africa Neuroendocrine Tumor Treatment Market Overview
29.2. Africa Neuroendocrine Tumor Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Neuroendocrine Tumor Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Neuroendocrine Tumor Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Neuroendocrine Tumor Treatment Market Competitive Landscape And Company Profiles

30.1. Neuroendocrine Tumor Treatment Market Competitive Landscape
30.2. Neuroendocrine Tumor Treatment Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. F Hoffmann-La Roche AG
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. AbbVie Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Novartis AG
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Sanofi SA
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Neuroendocrine Tumor Treatment Market Other Major And Innovative Companies

31.1. Bristol-Myers Squibb Company
31.2. Thermo Fisher Scientific Inc.
31.3. AstraZeneca
31.4. GlaxoSmithKline PLC
31.5. Takeda Pharmaceutical
31.6. Eli Lilly And Company
31.7. Amgen Inc.
31.8. Merck & Co. Inc.
31.9. Boehringer Ingelheim International GmbH
31.10. Servier
31.11. Teva Pharmaceutical Industries Ltd.
31.12. Ipsen Pharma SAS
31.13. Exelixis Inc.
31.14. Advanced Accelerator Applications SA
31.15. Hutchison Medipharma Ltd.

32. Global Neuroendocrine Tumor Treatment Market Competitive Benchmarking

33. Global Neuroendocrine Tumor Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Neuroendocrine Tumor Treatment Market

35. Neuroendocrine Tumor Treatment Market Future Outlook and Potential Analysis

35.1 Neuroendocrine Tumor Treatment Market In 2028 - Countries Offering Most New Opportunities
35.2 Neuroendocrine Tumor Treatment Market In 2028 - Segments Offering Most New Opportunities
35.3 Neuroendocrine Tumor Treatment Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer